LeonaBio, Inc. (NASDAQ:LONA) — Market Cap & Net Worth
Market Cap & Net Worth: LeonaBio, Inc. (LONA)
LeonaBio, Inc. (NASDAQ:LONA) has a market capitalization of $63.78 Million ($63.78 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21038 globally and #4747 in its home market, demonstrating a -15.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LeonaBio, Inc.'s stock price $6.79 by its total outstanding shares 9393514 (9.39 Million). Also see LONA total asset value for a full breakdown of the balance sheet.
LeonaBio, Inc. Market Cap History: 2026 to 2026
LeonaBio, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $63.78 Million to $63.78 Million (0.00% CAGR). Also see LeonaBio, Inc. (LONA) cash flow conversion for how efficiently the company converts equity into cash flow.
LeonaBio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LeonaBio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LONA share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LONA by Market Capitalization
Companies near LeonaBio, Inc. in the global market cap rankings as of September 18, 2026. Review LONA goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to LeonaBio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
LeonaBio, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, LeonaBio, Inc.'s market cap moved from $63.78 Million to $ 63.78 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $63.78 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of LeonaBio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $63.78 Million USD |
| MoneyControl | $63.78 Million USD |
| MarketWatch | $63.78 Million USD |
| marketcap.company | $63.78 Million USD |
| Reuters | $63.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more